An investigation on behalf of investors, who currently hold shares of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP), was announced concerning whether the takeover of Juniper Pharmaceuticals, Inc. by Catalent, Inc is unfair to NASDAQ: JNP stockholders.

The investigation by a law firm concerns whether certain officers and directors of Juniper Pharmaceuticals, Inc. breached their fiduciary duties owed to NASDAQ: JNP investors in connection with the proposed acquisition.

On Boston, MA based Juniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. On July 3, 2018, Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) announced it has entered into an agreement with Catalent, Inc. for Catalent to acquire all of the outstanding shares of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) at a price of $11.50 per share in cash.

However, given that at least one analyst has set the high target price for NASDAQ:JNP shares at $20.00 per share, the investigation concerns whether the offer is unfair to NASDAQ: JNP stockholders. More specifically, the investigation concerns whether the Juniper Pharmaceuticals Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.